Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 4,663 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Respiratory Therapy Clear all
Completed Not applicable Interventional

Adaptation of the Pediatric Asthma Control & Communication Instrument (PACCI) in a Pediatric Emergency Department

NCT01895478
View directory record Official record
Conditions
Asthma
Interventions
PACCI-ED use
Behavioral
Lead sponsor
Rhode Island Hospital
Other
Eligibility
1 Year to 17 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jul 10, 2013 · Synced Oct 22, 2026, 5:16 AM EDT
Completed Not applicable Interventional

The Impact of Holding on Stress and Bonding in Mother-Infant Pairs During Therapeutic Hypothermia

NCT03837717
View directory record Official record
Conditions
Hypoxic-Ischemic Encephalopathy, Neonatal Encephalopathy
Interventions
Holding, Saliva collection, No Holding
Behavioral · Other
Lead sponsor
MaineHealth
Other
Eligibility
24 Hours to 2 Days
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Portland, Maine
Source: ClinicalTrials.gov public record
Updated Dec 17, 2021 · Synced Oct 22, 2026, 5:16 AM EDT
Terminated Not applicable Interventional

PAL to Improve Oral Feeding for Infants With Chronic Lung Disease

NCT05446389
View directory record Official record
Conditions
Chronic Lung Disease of Prematurity, Respiratory Distress Syndrome in Premature Infant, Bronchopulmonary Dysplasia, Preterm Birth
Interventions
Pacifier Activated Lullaby ®
Device
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
1 Day to 33 Weeks
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Oct 22, 2026, 5:16 AM EDT
Completed Not applicable Interventional Results available

Performance and Safety of Biology-Guided Radiotherapy Using the RefleXion Medical Radiotherapy System (BIOGUIDE-X)

NCT04788147
View directory record Official record
Conditions
Cancer, Tumor, Solid, Cancer, Lung, Cancer, Bone, Metastasis to Lung, Metastasis to Bone
Interventions
RMRS IDE Device
Device
Lead sponsor
RefleXion Medical
Industry
Eligibility
22 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
2
States / cities
Stanford, California • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 31, 2023 · Synced Oct 22, 2026, 5:16 AM EDT
Terminated Phase 3 Interventional Results available

Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer

NCT01244191
View directory record Official record
Conditions
Non Squamous, Non-small-cell Lung Cancer
Interventions
Tivantinib, Placebo, Erlotinib
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
1,048 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
111
States / cities
Tucson, Arizona • Los Angeles, California • Oxnard, California + 85 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2021 · Synced Oct 22, 2026, 5:16 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer

NCT02289690
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Veliparib, Carboplatin, Etoposide, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
9
States / cities
Scottsdale, Arizona • Aurora, Colorado • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated May 14, 2020 · Synced Oct 22, 2026, 5:16 AM EDT
Terminated Phase 2 Interventional Results available

Pembrolizumab vs Topotecan in Patients With Small Cell Lung Cancer

NCT02963090
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Topotecan, Pembrolizumab
Drug
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Saint Louis Park, Minnesota • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Oct 22, 2026, 5:16 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy and Computer-Planned Radiation Therapy in Treating Patients With Unresectable Stage III Non-Small Cell Lung Cancer

NCT00033553
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, gemcitabine hydrochloride, paclitaxel, radiation therapy
Drug · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
74
States / cities
Anniston, Alabama • La Jolla, California • Los Angeles, California + 55 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2016 · Synced Oct 22, 2026, 5:16 AM EDT
Completed Phase 2 Interventional Results available

Dimethyl Fumarate for Obstructive Sleep Apnea

NCT02438137
View directory record Official record
Conditions
Obstructive Sleep Apnea, OSA, Sleep Apnea
Interventions
Dimethyl fumarate, Placebo
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Oct 22, 2026, 5:16 AM EDT
Completed Phase 2 Interventional Results available

A Study Evaluating the Effect of Inhaled PT007(AS MDI) Versus Placebo MDI and Ventolin Evohaler on Lung Function in Adult Participants With Asthma

NCT06644924
View directory record Official record
Conditions
Asthma
Interventions
Intervention: AS MDI, Intervention: Ventolin Evohaler, Intervention: Placebo matching AS MDI
Combination Product
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
22
States / cities
Encinitas, California • Lancaster, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 22, 2026, 5:16 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors

NCT07278479
View directory record Official record
Conditions
Large Cell Neuroendocrine Carcinoma, Large Cell Pulmonary Neuroendocrine Carcinoma of the Lung (LCNEC), Extrapulmonary Neuroendocrine Carcinoma (EP-NEC), Small Cell Lung Cancer (SCLC), Gastroenteropancreatic NEC (GEP NEC), NEC of the Bladder, Other DLL3 Expressing epNEC
Interventions
[212Pb]Pb-MP0712, [203Pb]Pb-MP0712
Drug · Other
Lead sponsor
Molecular Partners AG
Industry
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
8
States / cities
Tampa, Florida • Atlanta, Georgia • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 22, 2026, 5:16 AM EDT
Not listed Early Phase 1 Interventional

Evaluating Efficacy of Smart Device in Assisting With Inhaler Technique and Adherence

NCT04250779
View directory record Official record
Conditions
Asthma, Adherence, Medication, Childhood Asthma
Interventions
CapMedic smart inhaler device, Video-based guidance
Device · Behavioral
Lead sponsor
Landon Pediatric Foundation
Other
Eligibility
8 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Oct 22, 2026, 5:16 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer

NCT05005273
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Nivolumab, Ipilimumab, BMS-986207, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
17
States / cities
Tucson, Arizona • Fountain Valley, California • Fort Myers, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 22, 2026, 5:16 AM EDT
Not listed Phase 3 Interventional

Bronchoprovocation Study to Evaluate the Pharmacodynamics of Albuterol Sulfate Inhalation Aerosol, eq 90 mcg Base

NCT03549897
View directory record Official record
Conditions
Asthma
Interventions
Placebo, 90 mcg Reference Product, 180 mcg Reference Product, 90 mcg Test Product
Drug
Lead sponsor
Amneal Ireland Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Brookhaven, New York
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Oct 22, 2026, 5:16 AM EDT
Recruiting Phase 1 Interventional

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer

NCT05098210
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Cutaneous Melanoma, Locally Advanced Mucosal Melanoma, Metastatic Acral Melanoma, Metastatic Conjunctival Melanoma, Metastatic Cutaneous Melanoma, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Mucosal Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Recurrent Cutaneous Melanoma, Recurrent HER2-Negative Breast Carcinoma, Recurrent Hormone Receptor-Positive Breast Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Recurrent Mucosal Melanoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Unresectable Acral Melanoma, Unresectable Cutaneous Melanoma, Unresectable Lung Non-Small Cell Carcinoma, Unresectable Mucosal Melanoma
Interventions
Neoantigen Peptide Vaccine, Nivolumab, Poly ICLC, Echocardiography Test, Multigated Acquisition Scan, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Positron Emission Tomography, Ruxolitinib
Biological · Drug · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 22, 2026, 5:16 AM EDT
Completed Phase 2 Interventional Results available

COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Master Protocol

NCT04662086
View directory record Official record
Conditions
Covid19
Interventions
Acebilustat, Camostat
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Pleasanton, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 22, 2026, 5:16 AM EDT
Completed Phase 2 Interventional Results available

Stereotactic Body Radiation Therapy in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer That Can Be Removed By Surgery

NCT00551369
View directory record Official record
Conditions
Lung Cancer
Interventions
SBRT
Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
19
States / cities
Birmingham, Alabama • Berkeley, California • Carmichael, California + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2019 · Synced Oct 22, 2026, 5:16 AM EDT
Completed Phase 4 Interventional Results available

Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1)

NCT00617305
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Ambrisentan, Placebo, Sildenafil, Tadalafil
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
16 Years to 75 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
30
States / cities
Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2012 · Synced Oct 22, 2026, 5:16 AM EDT
Completed Phase 2 Interventional Results available

Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)

NCT00696020
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
BI 1744 CL/tiotropium bromide fixed dose combination, tiotropium bromide, Respimat® Inhaler
Drug · Device
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
22
States / cities
Riverside, California • San Diego, California • Wheat Ridge, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2015 · Synced Oct 22, 2026, 5:16 AM EDT
Recruiting Phase 2Phase 3 Interventional

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

NCT07100080
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Iza-bren, Carboplatin, Cisplatin, Pemetrexed
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
28
States / cities
Irvine, California • Orange, California • Edwards, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 22, 2026, 5:16 AM EDT
Terminated Phase 1Phase 2 Interventional

A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours

NCT05363605
View directory record Official record
Conditions
Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma, Bladder Carcinoma, Susceptible FGFR3 Genetic Alterations, FGFR3, FGFR3 Overexpression, FGFR3 Receptor, FGFR3 Protein Overexpression, Ovarian Cancer, Colorectal Cancer, Breast Cancer, Liver Cancer, Lung Cancer, Gastric Cancer
Interventions
[225Ac]-FPI-1966, [111In]-FPI-1967, vofatamab
Drug · Biological
Lead sponsor
Fusion Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
4
States / cities
Duarte, California • San Francisco, California • Iowa City, Iowa + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2023 · Synced Oct 22, 2026, 5:16 AM EDT
Completed Phase 1 Interventional

Vitamin D Testing and Treatment for COVID 19

NCT04407286
View directory record Official record
Conditions
Covid 19, Vitamin D Deficiency
Interventions
Vitamin D3
Dietary Supplement
Lead sponsor
Arizona State University
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 30, 2021 · Synced Oct 22, 2026, 5:16 AM EDT
Terminated Phase 3 Interventional Results available

PF-07304814 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

NCT05780541
View directory record Official record
Conditions
COVID-19
Interventions
PF-07304814, Placebo, Remdesivir
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
31
States / cities
Chula Vista, California • Los Angeles, California • Mather, California + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2024 · Synced Oct 22, 2026, 5:16 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)

NCT03521154
View directory record Official record
Conditions
Non Small Cell Lung Cancer (Stage III)
Interventions
Osimertinib 80mg/40mg, Placebo Osimertinib 80mg/40mg
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
5
States / cities
Duarte, California • Atlanta, Georgia • Florham Park, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 22, 2026, 5:16 AM EDT